Childhood Hematopoietic Cell Transplantation (PDQ®)–Health Professional Version
SECTIONS
- General Information About Hematopoietic Cell Transplantation (HCT)
- Autologous HCT
- Allogeneic HCT
- Complications After HCT
- Late Effects After HCT in Children
- Current Clinical Trials
- Changes to This Summary (04/04/2018)
- About This PDQ Summary
- View All Sections
Changes to This Summary (04/04/2018)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added text to state that decreased veno-occlusive disease (VOD) mortality was associated with the early initiation of defibrotide treatment soon after diagnostic criteria for sinusoidal obstructive syndrome (SOS)/VOD were met (cited Richardson et al. as reference 30 and level of evidence 2A).
Added text to state that defibrotide is approved by the U.S. Food and Drug Administration for patients who have hepatic SOS/VOD with renal or pulmonary dysfunction after hematopoietic stem cell transplantation.
This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
No hay comentarios:
Publicar un comentario